| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1375566 | Bioorganic & Medicinal Chemistry Letters | 2009 | 4 Pages |
Abstract
Compound 1 (SNS-314) is a potent and selective Aurora kinase inhibitor that is currently in clinical trials in patients with advanced solid tumors. This communication describes the synthesis of prodrug derivatives of 1 with improved aqueous solubility profiles. In particular, phosphonooxymethyl-derived prodrug 2g has significantly enhanced solubility and is converted to the biologically active parent (1) following iv as well as po administration to rodents.
Graphical abstractIn vitro and in vivo properties of prodrug derivatives of the Aurora kinase inhibitor SNS-314 are described.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Johan D. Oslob, Stacey A. Heumann, Chul H. Yu, Darin A. Allen, Subramanian Baskaran, Minna Bui, Erlie Delarosa, Amy D. Fung, Ahmad Hashash, Jonathan Hau, Sheryl Ivy, Jeffrey W. Jacobs, Willard Lew, Jack Maung, Robert S. McDowell, Sean Ritchie,